Judith Guasch

Judith Guasch

Auto-generated profile, based on publicly available information

Judith Guasch

Institute of Materials Science of Barcelona (ICMAB-CSIC), Campus UAB, Bellaterra 08193, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2017 in Nano Letters
Verified
Journal Article
Closed access
JGJudith Guasch
Judith Guasch
CMChristine A. Muth
Christine A. Muth
JDJennifer Diemer
Jennifer Diemer
HRHossein Riahinezhad
Hossein Riahinezhad
JSJoachim Pius Spatz
Joachim Pius Spatz

1 November 2020 in Biomaterials
Verified
Journal Article
Open access
EREduardo Pérez del Río
Eduardo Pérez del Río
FSFabião Santos
Fabião Santos
XRXavier Rodriguez Rodriguez
Xavier Rodriguez Rodriguez
MMMarc Martínez-Miguel
Marc Martínez-Miguel
RRRamon Roca-Pinilla
Ramon Roca-Pinilla
JGJudith Guasch
Judith Guasch
Recent achievements in the field of immunotherapy, such as the development of engineered T cells used in adoptive cell therapy, are introducing more efficient strategies to combat cancer. Nevertheless, there are still many limitations. For example, these T cells are challenging to manufacture, manipulate, and control. Specifically, there are limitations in producing the large amounts of therapeutic T cells needed for these therapies in a short period of time and in an economically viable manner. In this study, three-dimensional (3D) poly(ethylene) glycol (PEG) hydrogels covalently combined with low molecular weight heparin are engineered to resemble the lymph nodes, where T cells reproduce. In these hydrogels, PEG provides the needed structural and mechanical properties, whereas heparin is used as an anchor for the cytokine CCL21, which is present in the lymph nodes, and can affect cell migration and proliferation. The 3D structure of the hydrogel in combination with its loading capacity result in an increased primary human CD4+ T cell proliferation compared to the state-of-the-art expansion systems consisting of artificial antigen presenting cells. Thus, we present a new tool for adoptive cell therapy to help achieving the large numbers of cells required for therapy of selected phenotypes targeted against cancer cells, by mimicking the lymph nodes.

22 April 2013 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JGJudith Guasch
Judith Guasch
LGLuca Grisanti
Luca Grisanti
Manuel SoutoManuel Souto
Manuel Souto
Vega LloverasVega Lloveras
Vega Lloveras
José Vidal-GancedoJosé Vidal-Gancedo
José Vidal-Gancedo
JVJaume Veciana
Jaume Veciana

13 August 2008 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
GDGabriele D'Avino
Gabriele D'Avino
LGLuca Grisanti
Luca Grisanti
JGJudith Guasch
Judith Guasch
Imma RateraImma Ratera
Imma Ratera
JVJaume Veciana
Jaume Veciana
APAnna Painelli
Anna Painelli

6 June 2013 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
FRFlorian Rechenmacher
Florian Rechenmacher
SNStefanie Neubauer
Stefanie Neubauer
Carles Mas MorunoCarles Mas Moruno
Carles Mas Moruno
PDPetra M. Dorfner
Petra M. Dorfner
JPJulien Polleux
Julien Polleux
HKHorst Kessler
Horst Kessler

28 February 2013 in Chemistry of Materials
Verified
Journal Article
Closed access
JGJudith Guasch
Judith Guasch
LGLuca Grisanti
Luca Grisanti
SJStefan Jung
Stefan Jung
DMDayana Morales
Dayana Morales
GDGabriele D'Avino
Gabriele D'Avino
JVJaume Veciana
Jaume Veciana